Clinical trial · Interventional
Dynamics of 18-FDG Uptake in Stage III/IV Non Small Cell Lung Cancer During First Line Pembrolizumab Treatment
18-FDG Tumour Metabolism Changes in PDL1 Superior to 50% Stage III/IV Non Small Cell Lung Cancer During First Line Treatment With Pembrolizumab
NCT03832348CI-TRIAL-00100038iTEP1completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to describe the early dynamics of 18-FDG uptake in non smal cell lung cancer during first line treatment with pembrolizumab, and to evaluate whether or not they differ according to treatment response at 3 months.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET scan imaging | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- PET scan imaging
- description
- PET scan will be performed each of three first cycles of pembrolizumab to describe the early tumour metabolic changes during the first line of treatment.
- interventionNames
- Device: PET scan imaging
Primary outcomes (1)
- measure
- Determination of progression by early PET scan
- timeFrame
- 3 months
- description
- Determination of non-response of treatment by PET scan imaging after one cycle of Pembrolizumab
Secondary outcomes (2)
- measure
- Progression free survival
- timeFrame
- 24 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Non operable non small cell lung cancer * Indication of treatment by Pembrolizumab * PD-L1 status superior to 50 % * Age more than 18 years * At least one measurable target * Written inform consent Exclusion Criteria: * no treatment by pembrolizumab * immunosuppressive treatment * uncontrolled diabete * Pregnancy or breast-feeding * curatorship or guardianship * not possibility to follow-up the procedures of the study due to geographic, social or psychic reasons
References
Publications (0)
Data not yet available
No reference posted for this study.